AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of BRL 1.59 trillion. The enterprise value is 1.71 trillion.

Market Cap	1.59T
Enterprise Value	1.71T

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Feb 19, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	0.03%
Owned by Institutions (%)	66.82%
Float	1.54B

Valuation Ratios

The trailing PE ratio is 28.18 and the forward PE ratio is 18.82.

PE Ratio	28.18
Forward PE	18.82
PS Ratio	4.91
PB Ratio	5.91
P/TBV Ratio	n/a
P/FCF Ratio	24.49
P/OCF Ratio	19.77
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.60, with an EV/FCF ratio of 26.44.

EV / Earnings	30.42
EV / Sales	5.56
EV / EBITDA	16.60
EV / EBIT	22.87
EV / FCF	26.44

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.

Current Ratio	0.94
Quick Ratio	0.65
Debt / Equity	0.61
Debt / EBITDA	1.51
Debt / FCF	2.52
Interest Coverage	10.47

Financial Efficiency

Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.48%.

Return on Equity (ROE)	22.84%
Return on Assets (ROA)	8.19%
Return on Invested Capital (ROIC)	16.48%
Return on Capital Employed (ROCE)	17.12%
Weighted Average Cost of Capital (WACC)	5.16%
Revenue Per Employee	3.37M
Profits Per Employee	586,049
Employee Count	96,100
Asset Turnover	0.54
Inventory Turnover	1.81

Taxes

In the past 12 months, AstraZeneca has paid 11.95 billion in taxes.

Income Tax	11.95B
Effective Tax Rate	17.49%

Stock Price Statistics

The stock price has increased by +14.50% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	+14.50%
50-Day Moving Average	169.92
200-Day Moving Average	149.92
Relative Strength Index (RSI)	47.12
Average Volume (20 Days)	635

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of BRL 323.53 billion and earned 56.32 billion in profits. Earnings per share was 36.02.

Revenue	323.53B
Gross Profit	264.35B
Operating Income	78.72B
Pretax Income	68.31B
Net Income	56.32B
EBITDA	106.19B
EBIT	78.72B
Earnings Per Share (EPS)	36.02

Full Income Statement

Balance Sheet

The company has 31.50 billion in cash and 163.60 billion in debt, giving a net cash position of -132.10 billion.

Cash & Cash Equivalents	31.50B
Total Debt	163.60B
Net Cash	-132.10B
Net Cash Per Share	n/a
Equity (Book Value)	268.34B
Book Value Per Share	172.84
Working Capital	-10.43B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 80.28 billion and capital expenditures -15.48 billion, giving a free cash flow of 64.80 billion.

Operating Cash Flow	80.28B
Capital Expenditures	-15.48B
Free Cash Flow	64.80B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.

Gross Margin	81.71%
Operating Margin	24.33%
Pretax Margin	21.11%
Profit Margin	17.41%
EBITDA Margin	32.82%
EBIT Margin	24.33%
FCF Margin	20.03%

Dividends & Yields

This stock pays an annual dividend of 2.70, which amounts to a dividend yield of 1.58%.

Dividend Per Share	2.70
Dividend Yield	1.58%
Dividend Growth (YoY)	-2.79%
Years of Dividend Growth	4
Payout Ratio	7.50%
Buyback Yield	0.06%
Shareholder Yield	1.61%
Earnings Yield	3.55%
FCF Yield	4.08%

Dividend Details

Stock Splits

The last stock split was on February 2, 2026. It was a reverse split with a ratio of 0.5.

Last Split Date	Feb 2, 2026
Split Type	Reverse
Split Ratio	0.5

Scores

AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 7.

Altman Z-Score	3.24
Piotroski F-Score	7